Global X Cloud Computing ETF vs Sana Biotechnology Inc — how do they compare? Global X Cloud Computing ETF trades at $28.03, while Sana Biotechnology Inc trades at $3.74 (market cap $1.13B). The key difference: Global X Cloud Computing ETF is trading nearer its 52-week high, Sana Biotechnology Inc nearer its low. Which is the better fit depends on your goals.
| CLOU | SANA | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $28.09 | $5.92 |
52-Week Low | $17.60 | $2.68 |
Market Cap | — | $1.13B |
Enterprise Value | — | $1.05B |
Signals from Pluang's Aura AI — not financial advice
CLOU, the Global X Cloud Computing ETF, trades at $27.77, down 1.14% today, with technical indicators showing a bullish trend from moving averages but overbought signals from RSI levels above 83. The ETF offers diversified exposure to cloud computing stocks like Snowflake and Datadog, benefiting from long-term growth drivers in digital transformation.
The outlook remains positive due to strong non-AI growth factors and resilient subscription revenues, though risks include sector volatility and competitive pressures. Analyst sentiment is bullish, with buy ratings highlighting growth potential beyond short-term hype.
SANA Biotechnology trades at $3.77, up 4.43% on the day, with a bullish technical signal from moving averages and oscillators despite overbought RSI readings. The company reported a net loss of $244.17 million in 2025, with negative cash flow from operations, but analyst sentiment is strong with 82% buy ratings. Recent news highlights clinical data presentations and a $9.50 consensus price target from brokerages as of July 30, 2026.
The outlook hinges on clinical progress in engineered cell therapies, with upside potential from positive trial outcomes, but risks include persistent cash burn and execution challenges. Investors face high volatility given the pre-revenue biotech profile and dependence on financing activities to sustain operations.
Trailing returns across standard periods
Latest headlines on both assets
CLOU is a thematic ETF that invests in companies leading the cloud revolution. It targets providers of SaaS, PaaS, and IaaS, including major firms like Salesforce, Akamai, and Shopify that drive modern digital infrastructure.
Read more on CLOU →Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →